Literature DB >> 9000663

Patterns of viremia in liver transplant recipients with symptomatic cytomegalovirus infection.

D Mutimer1, A Matyi-Toth, J Shaw, E Elias, K O'Donnell, P Stalhandske.   

Abstract

Cytomegalovirus (CMV) titer in blood seems to be the principal determinant of clinical symptoms in immunosuppressed patients. We have developed an assay for quantitation of CMV DNA in serum. The assay requires the coamplification by polymerase chain reaction (PCR) of extracted serum DNA with 1000 molecules of mutated internal standard DNA, and then an ELISA detection system. We examined 133 paired buffy coats and sera from 15 patients with symptomatic infection. Sera were examined by quantitative PCR, and buffy coats were examined by qualitative PCR (with a detection threshold of approximately 40 copies per 150,000 cells). Serum viral titers peaked during the seventh week after transplant (median day 40, range 26-58) at about the time of symptom onset. Mean viral titer measured during the seventh week was 1.2 x 10(5) copies per milliliter of serum (standard error 6.5 x 10(4). Buffy-coat PCR results were generally concordant with results of serum PCR (overall concordance 103/133=77.4%). Serum CMV titer fell, as symptoms resolved with reduction of immunosuppression and specific antiviral therapy. High titers and poor response to antiviral therapy were observed in the context of excessive immunosuppression and bacterial sepsis. Measurement of serum CMV titer may be useful for the management of immunosuppressed transplant recipients, and provides a tool for the better understanding of factors that enhance or inhibit viral replication.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9000663     DOI: 10.1097/00007890-199701150-00013

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  6 in total

1.  Enhanced analytical sensitivity of a quantitative PCR for CMV using a modified nucleic-acid extraction procedure.

Authors:  A Ferreira-Gonzalez; S Yanovich; M R Langley; L A Weymouth; D S Wilkinson; C T Garrett
Journal:  J Clin Lab Anal       Date:  2000       Impact factor: 2.352

Review 2.  New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipients.

Authors:  I G Sia; R Patel
Journal:  Clin Microbiol Rev       Date:  2000-01       Impact factor: 26.132

3.  Qualitative and semiquantitative polymerase chain reaction testing for cytomegalovirus DNA in serum allows prediction of CMV related disease in liver transplant recipients.

Authors:  P C Evans; A Soin; T G Wreghitt; G J Alexander
Journal:  J Clin Pathol       Date:  1998-12       Impact factor: 3.411

Review 4.  Clinical utility of viral load in management of cytomegalovirus infection after solid organ transplantation.

Authors:  Raymund R Razonable; Randall T Hayden
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

5.  Measurement of human cytomegalovirus loads by quantitative real-time PCR for monitoring clinical intervention in transplant recipients.

Authors:  Haijing Li; J Stephen Dummer; Wray R Estes; Shufang Meng; Peter F Wright; Yi-Wei Tang
Journal:  J Clin Microbiol       Date:  2003-01       Impact factor: 5.948

Review 6.  Quantitation of cytomegalovirus: methodologic aspects and clinical applications.

Authors:  M Boeckh; G Boivin
Journal:  Clin Microbiol Rev       Date:  1998-07       Impact factor: 26.132

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.